1) As per protocol, when 75% of the planned 250 MACE events, being 188 events in total, have occurred, a sample size re-estimation analysis will be conducted assuring that the trial will be sufficiently powered to confirm relative risk reduction.

Still there, good.

2) commencement of revenue between late 2021 and 2023, based on clinical development paths across various jurisdictions, as at April 30, 2018 (April 30, 2017 and April 30, 2016 - between 2021 and 2023)

Their sales debut prediction was pushed back 6 months. Wondering why.